Impact of COVID-19-related restrictions on medical consultations and business activities
First written in FY2021-Q1. 7 of 12 entries say "Restated". Latest entry: FY2024-Q3.
Kaken Pharmaceutical moved to the "Worse" side of this theme in 2020, 2 years before the typical company in this theme (2022).
2 other companies' latest entry also says "Restated".
- FY2024-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company stated that there were no material changes during the nine-month period ended the third quarter of the current fiscal year to the major risks, including COVID-19. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company stated that there were no material changes during the six-month period ended the second quarter of the current fiscal year to the major risks. - FY2024-Q1RestatedAnnual report
「During the three-month period ended 30 June, there were no new risks that management recognizes as having the potential to materially affect the financial position, operating results or cash flows of the consolidated companies, and no material changes to the business risks described in the annual securities report for the previous fiscal year.」
The company stated that there were no material changes during the current quarter to the major risks, including COVID-19. - FY2023-Q3RestatedAnnual report
「There were no material changes during the nine-month period ended the third quarter of the current fiscal year to the accounting estimates related to the spread of COVID-19 described in the “Additional Information” section of the securities report for the previous consolidated fiscal year.」
The company stated that there were no material changes during the nine-month period ended the third quarter of the current fiscal year to the accounting estimates related to the spread of COVID-19. - FY2022RestatedAnnual report
「Regardless of the initiatives undertaken by our group, if the impact of COVID-19 worsens or persists for an extended period beyond our group's expectations, it may have a material impact on our group's operating results and financial position.」
The company has continued to disclose the possibility that a worsening or prolonged COVID-19 outbreak may affect business performance, financial position, the supply system and research and development activities. - FY2022-Q3RestatedAnnual report
「The business performance of our group has been affected by restrictions on visits to medical institutions and other factors associated with the spread of COVID-19, and we expect the impact to continue.」
The company explained that the impact of restrictions on visits to medical institutions and other factors continues to affect business performance. Meanwhile, revenue increased for the nine-month period ended the third quarter due to a rebound from the restrictions and contributions from new products. - FY2022-Q2RestatedAnnual report
「The business performance of our group has been affected by restrictions on visits to medical institutions and other factors associated with the spread of COVID-19, and we expect the impact to continue.」
Although revenue increased for the six-month period ended the second quarter due to a rebound from restrictions on visits to medical institutions and other factors, the company explained that the pandemic's impact on business performance continues. - FY2022-Q1SoftenedAnnual report
「Net sales were ¥18,453 million, up 2.1% year on year. Despite the impact of drug price revisions, revenue increased due in part to a rebound from patients refraining from visiting medical institutions as COVID-19 infections spread.」
While restrictions on visits to medical institutions caused revenue to decline in the previous fiscal year and the first quarter of the previous fiscal year, revenue for the first quarter of the current fiscal year increased 2.1% year on year due to a rebound from those restrictions and other factors. However, the company expects the impact of the pandemic to continue. - FY2021WorsenedAnnual report
「The business performance of our group has been affected by restrictions on visits to medical institutions and other factors associated with the spread of COVID-19, and we expect the impact to continue.」
The impact of COVID-19-related restrictions on visits to medical institutions resulted in lower revenue and profit for the full fiscal year, with consolidated revenue down 16.0% and operating profit down 32.9%. The company also revised downward its target for the final year of its medium-term management plan partly because of this impact. - FY2021-Q3WorsenedAnnual report
「The Group reported lower revenue and lower profit for the cumulative third quarter of the consolidated fiscal year. Net sales were ¥57,082 million, down 18.7% year on year. The main factors behind the decline included the impact of drug price revisions and patients refraining from visiting medical institutions as COVID-19 infections spread.」
The impact of COVID-19-related restrictions on visits to medical institutions has continued to appear in the form of a 18.7% decrease in revenue and a 33.4% decrease in operating profit, among other results. As in the previous quarter, the company expects the impact to continue. - FY2021-Q2MaterialisedAnnual report
「The business performance of our group has been affected by restrictions on visits to medical institutions and other factors associated with the spread of COVID-19, and we expect the impact to continue.」
The impact of COVID-19-related restrictions on visits to medical institutions has continued to appear in the form of a 18.6% decrease in revenue and a 28.8% decrease in operating profit, among other results. The company expects the impact to continue. - FY2021-Q1First statedAnnual report
「Regardless of the initiatives undertaken by our group, if the impact of COVID-19 worsens or persists for an extended period, it may affect the supply system for pharmaceuticals and research and development activities, and such effects may recur. Even if the spread of COVID-19 slows or subsides, it may continue to affect our group's business activities, financial position and operating results for a certain period.」
The company stated that COVID-19-related restrictions on visits to medical institutions are already appearing as a factor behind lower revenue, and that if the outbreak worsens or persists for an extended period, its effects on the supply system, research and development activities, business activities, financial position and operating results may continue.